Open AccessPulmonary Toxicity of Bleomycin – A Case Series from a Tertiary Care Center in Southern India
Author(s) -
Navin Patil,
Rinz Mathew Paulose,
Karthik Subramanya Udupa,
Narayanan Ramakrishna,
Talha Ahmed
Publication year - 2016
Publication title -
journal of clinical and diagnostic research
Language(s) - English
Resource type - Journals
eISSN - 2249-782X
pISSN - 0973-709X
DOI - 10.7860/jcdr/2016/18773.7626
Subject(s) - bleomycin , pulmonary toxicity , medicine , abvd , pulmonary fibrosis , toxicity , chemotherapy , regimen , lung , adverse effect , lymphoma , tertiary care , pneumonitis , gastroenterology , surgery , oncology , vincristine , cyclophosphamide
Hodgkin's lymphoma is one of the curable cancers and the standard treatment regimen involves combination chemotherapy involving bleomycin. One of the fatal side effect of bleomycin is pulmonary toxicity. Here we present three cases of Hodgkin's lymphoma treated with ABVD chemotherapy who had pulmonary toxicity. All three developed bleomycin induced pulmonary toxicity in the form of pulmonary fibrosis during treatment of the disease. Mode of treatment, severity of the condition and the treatment outcome varied among the three. Two recovered following treatment and one patient died due to irreversible pulmonary damage. Causality assessment using Naranjo's scale gave a score of 7 for case one and three and a score of 6 for case two, both indicating the adverse drug reaction to be a probable bleomycin induced Lung fibrosis.